
Ana I Robles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9352/publications.pdf Version: 2024-02-01



ANA L PORLES

#	Article	IF	CITATIONS
1	Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell, 2021, 39, 509-528.e20.	16.8	327
2	A proteogenomic portrait of lung squamous cell carcinoma. Cell, 2021, 184, 4348-4371.e40.	28.9	170
3	Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell, 2021, 184, 5031-5052.e26.	28.9	236
4	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell, 2020, 183, 1436-1456.e31.	28.9	273
5	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell, 2020, 183, 1962-1985.e31.	28.9	177
6	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell, 2020, 182, 200-225.e35.	28.9	410
7	Proteogenomic Characterization of Endometrial Carcinoma. Cell, 2020, 180, 729-748.e26.	28.9	296
8	Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability. Cell Reports Medicine, 2020, 1, 100004.	6.5	46
9	A small protein encoded by a putative lncRNA regulates apoptosis and tumorigenicity in human colorectal cancer cells. ELife, 2020, 9, .	6.0	43
10	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	28.9	430
11	Prenatal smoke exposure, DNA methylation and a link between DRD1 and lung cancer. International Journal of Epidemiology, 2019, 48, 1377-1378.	1.9	2
12	Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art. Pharmacogenomics Journal, 2019, 19, 5-14.	2.0	34
13	Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nature Communications, 2018, 9, 771.	12.8	356
14	HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients. Lung Cancer, 2018, 122, 151-159.	2.0	13
15	A Nucleolar Stress–Specific p53–miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network. EBioMedicine, 2018, 33, 33-48.	6.1	14
16	Inverse association of vitamin D ₃ levels with lung cancer mediated by genetic variation. Cancer Medicine, 2018, 7, 2764-2775.	2.8	14
17	Interaction between the microbiome and TP53 in human lung cancer. Genome Biology, 2018, 19, 123.	8.8	247
18	Integration of multiple "OMIC―biomarkers: A precision medicine strategy for lung cancer. Lung Cancer, 2017, 107, 50-58.	2.0	45

Ana I Robles

#	Article	IF	CITATIONS
19	Seeing the Forest through the Phylogenetic Tree. New England Journal of Medicine, 2017, 376, 2190-2191.	27.0	1
20	Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells. Cell Death and Differentiation, 2017, 24, 1017-1028.	11.2	49
21	Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutation Research - Reviews in Mutation Research, 2017, 771, 32-58.	5.5	30
22	Long Noncoding RNA PURPL Suppresses Basal p53 Levels and Promotes Tumorigenicity in Colorectal Cancer. Cell Reports, 2017, 20, 2408-2423.	6.4	120
23	Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surgical Oncology, 2017, 26, 278-285.	1.6	20
24	A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts. Journal of Thoracic Oncology, 2017, 12, 65-76.	1.1	26
25	Sputum-based DNA methylation biomarkers to guide lung cancer screening decisions. Journal of Thoracic Disease, 2017, 9, 4308-4310.	1.4	4
26	Liquid biopsy in early stage lung cancer. Translational Lung Cancer Research, 2016, 5, 517-524.	2.8	28
27	Methylation analyses in liquid biopsy. Translational Lung Cancer Research, 2016, 5, 492-504.	2.8	58
28	Gene expression classifier for prognosis of early-stage squamous cell carcinoma of the lung. Journal of Thoracic Oncology, 2016, 11, S38-S39.	1.1	1
29	The Werner syndrome RECQ helicase targets G4 DNA in human cells to modulate transcription. Human Molecular Genetics, 2016, 25, 2060-2069.	2.9	81
30	Clinical Outcomes of <i>TP53</i> Mutations in Cancers. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026294.	6.2	49
31	KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC. Annals of Oncology, 2016, 27, 360-361.	1.2	8
32	An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. Journal of Thoracic Oncology, 2015, 10, 1037-1048.	1.1	103
33	A Flexible Reporter System for Direct Observation and Isolation of Cancer Stem Cells. Stem Cell Reports, 2015, 4, 155-169.	4.8	110
34	Identification of a Functional SNP in the 3′UTR of CXCR2 That Is Associated with Reduced Risk of Lung Cancer. Cancer Research, 2015, 75, 566-575.	0.9	53
35	Cigarette smoke mediates epigenetic repression of miR-217 during esophageal adenocarcinogenesis. Oncogene, 2015, 34, 5548-5559.	5.9	32
36	Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis, 2015, 36, 616-621.	2.8	73

ANA I ROBLES

#	Article	IF	CITATIONS
37	Germline variation in <i>NCF4</i> , an innate immunity gene, is associated with an increased risk of colorectal cancer. International Journal of Cancer, 2014, 134, 1399-1407.	5.1	70
38	A <i>DRD1</i> Polymorphism Predisposes to Lung Cancer among Those Exposed to Secondhand Smoke during Childhood. Cancer Prevention Research, 2014, 7, 1210-1218.	1.5	25
39	Regulation of gene expression by the BLM helicase correlates with the presence of G-quadruplex DNA motifs. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9905-9910.	7.1	108
40	The Expression of Four Genes as a Prognostic Classifier for Stage I Lung Adenocarcinoma in 12 Independent Cohorts. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2884-2894.	2.5	24
41	Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence. Oncogene, 2013, 32, 2792-2798.	5.9	127
42	Inflammation-Mediated Genetic and Epigenetic Alterations Drive Cancer Development in the Neighboring Epithelium upon Stromal Abrogation of TGF-β Signaling. PLoS Genetics, 2013, 9, e1003251.	3.5	69
43	Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma. Cancer Research, 2013, 73, 3821-3832.	0.9	52
44	A primate-specific microRNA enters the lung cancer landscape. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18748-18749.	7.1	6
45	miRNA Signature of Mouse Helper T Cell Hyper-Proliferation. PLoS ONE, 2013, 8, e66709.	2.5	8
46	3′-UTR and Functional Secretor Haplotypes in Mannose-Binding Lectin 2 Are Associated with Increased Colon Cancer Risk in African Americans. Cancer Research, 2012, 72, 1467-1477.	0.9	68
47	Functional Interaction of Tumor Suppressor DLC1 and Caveolin-1 in Cancer Cells. Cancer Research, 2012, 72, 4405-4416.	0.9	42
48	KRAS-LCS6 Genotype as a Prognostic Marker in Early-Stage CRC–Letter. Clinical Cancer Research, 2012, 18, 3487-3488.	7.0	27
49	rs4919510 in hsa-mir-608 Is Associated with Outcome but Not Risk of Colorectal Cancer. PLoS ONE, 2012, 7, e36306.	2.5	85
50	MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer. International Journal of Cancer, 2012, 131, 2710-2716.	5.1	20
51	Genetic variation in microRNA networks: the implications for cancer research. Nature Reviews Cancer, 2010, 10, 389-402.	28.4	1,184
52	Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2195-2200.	7.1	122
53	Clinical Outcomes and Correlates of TP53 Mutations and Cancer. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001016-a001016.	5.5	237
54	Targeted Disruption of Ing2 Results in Defective Spermatogenesis and Development of Soft-Tissue Sarcomas. PLoS ONE, 2010, 5, e15541.	2.5	43

ANA I ROBLES

#	Article	IF	CITATIONS
55	WNT16B Is a New Marker of Cellular Senescence That Regulates p53 Activity and the Phosphoinositide 3-Kinase/AKT Pathway. Cancer Research, 2009, 69, 9183-9191.	0.9	91
56	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8368-8373.	7.1	286
57	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas. Nature Medicine, 2009, 15, 1369-1376.	30.7	149
58	A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis. FEBS Letters, 2008, 582, 3868-3874.	2.8	19
59	Harnessing genetically engineered mouse models for preclinical testing. Chemico-Biological Interactions, 2008, 171, 159-164.	4.0	15
60	HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Molecular Cancer Therapeutics, 2008, 7, 1985-1992.	4.1	70
61	Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models. Clinical Cancer Research, 2007, 13, 2168-2177.	7.0	44
62	Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance. Cancer Research, 2007, 67, 10397-10405.	0.9	118
63	Synergy of the Purine-Scaffold HSP90 Inhibitor, PU-H71, with Doxorubicin in Non-Hodgkin's Lymphoma Cell Lines Blood, 2007, 110, 1399-1399.	1.4	2
64	Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines. Clinical Cancer Research, 2006, 12, 6547-6556.	7.0	35
65	The p53 Tumor Suppressor Network Is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress. Cancer Research, 2005, 65, 10255-10264.	0.9	93
66	Nitric Oxide Is a Signaling Molecule that Regulates Gene Expression. Methods in Enzymology, 2005, 396, 326-340.	1.0	14
67	Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. Journal of Cell Biology, 2004, 166, 801-813.	5.2	118
68	p53-Induced Up-Regulation of MnSOD and GPx but not Catalase Increases Oxidative Stress and Apoptosis. Cancer Research, 2004, 64, 2350-2356.	0.9	326
69	Apoptotic Signaling Pathways Induced by Nitric Oxide in Human Lymphoblastoid Cells Expressing Wild-Type or Mutant p53. Cancer Research, 2004, 64, 3022-3029.	0.9	64
70	p53. Chest, 2004, 125, 83S-85S.	0.8	16
71	Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature Medicine, 2003, 9, 416-423.	30.7	805
72	The p53 network in lung carcinogenesis. Oncogene, 2002, 21, 6898-6907.	5.9	130

ANA I ROBLES

#	Article	IF	CITATIONS
73	Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Research, 2002, 62, 3244-50.	0.9	123
74	Functional Interaction of p53 and BLM DNA Helicase in Apoptosis. Journal of Biological Chemistry, 2001, 276, 32948-32955.	3.4	129
75	Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. Oncogene, 1999, 18, 4681-4688.	5.9	48
76	p53-Mediated apoptosis is attenuated in Werner syndrome cells. Genes and Development, 1999, 13, 1355-1360.	5.9	161
77	Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes and Development, 1998, 12, 2469-2474.	5.9	202
78	Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7634-7638.	7.1	155
79	Positive immunohistochemical staining of p53 and cyclin D in advanced mouse skin tumors, but not in precancerous lesions produced by benzo[a]pyrene. Carcinogenesis, 1995, 16, 1629-1635.	2.8	28
80	Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis, 1995, 16, 781-786.	2.8	87
81	Low frequency of codon 61 Ha-ras mutations and lack of keratin 13 expression in 7,12-dimethylbenz[a]-anthracene—induced hamster skin tumors. Molecular Carcinogenesis, 1993, 7,	2.7	9